Progression risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.

Francesco Pinto, Marco Racioppi, Emilio Sacco, Angelo Totaro, Antonio Brescia, Andrea Volpe, Mario Gardi, Pier Francesco Bassi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Benign prostatic hyperplasia (BPH) is a chronic common disease in many men and is often associated with bothersome lower urinary tract symptoms (LUTS). In many men the disease presents with a progressive course that can result in complications such as acute urinary retention (AUR) and BPH-related surgery. Several factors have been associated with progression such as age and prostate volume (PV). Serum prostate-specific antigen (PSA) level, closely correlated with PV, is another useful parameter for determining the risk of BPH progression. Medical therapy is the first and the most frequently used treatment for BPH; surgical treatments rapresent a second-line option when medical therapy is non effective or when complications are associated. Alpha-blockers achieve rapid symptom relief but do not reduce the overall risk of AUR or BPH-related surgery, presumably because they have no effect on PV. 5alpha-reductase inhibitors (5ARIs) display their effectiveness at long distance decreasing PV; this results in improved symptoms, urinary flow and quality of life, and a reduced risk of AUR and BPH-related surgery. Combination therapy provides greater and more durable benefits than either monotherapy and is a recommended option in treatment guidelines. The Combination of dutasteride and Tamsulosin (CombAT), at a pre-planned 2-year analysis, has shown sustained symptom improvement with combination therapy, significantly greater than with either monotherapy. CombAT is also the first study to show benefit in improving BPH symptoms for combination therapy over the alpha-blocker, tamsulosin, from 9 months of treatment. PubMed database has been used to identify publications on the epidemiology of BPH, risk factors for BPH progression and drug treatment options for the management of BPH.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalArchivio Italiano di Urologia e Andrologia
Volume81
Issue number1
Publication statusPublished - Mar 2009

Fingerprint

Prostatic Hyperplasia
tamsulosin
Urinary Retention
Prostate
Therapeutics
Lower Urinary Tract Symptoms
Prostate-Specific Antigen
PubMed
Publications
Oxidoreductases
Epidemiology
Chronic Disease
Quality of Life
Databases
Guidelines

Keywords

  • Benign prostatic hyperplasia
  • Diagnosis
  • Risk factors
  • Therapy.

ASJC Scopus subject areas

  • Urology

Cite this

Progression risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia. / Pinto, Francesco; Racioppi, Marco; Sacco, Emilio; Totaro, Angelo; Brescia, Antonio; Volpe, Andrea; Gardi, Mario; Bassi, Pier Francesco.

In: Archivio Italiano di Urologia e Andrologia, Vol. 81, No. 1, 03.2009, p. 1-8.

Research output: Contribution to journalArticle

Pinto, F, Racioppi, M, Sacco, E, Totaro, A, Brescia, A, Volpe, A, Gardi, M & Bassi, PF 2009, 'Progression risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.', Archivio Italiano di Urologia e Andrologia, vol. 81, no. 1, pp. 1-8.
Pinto, Francesco ; Racioppi, Marco ; Sacco, Emilio ; Totaro, Angelo ; Brescia, Antonio ; Volpe, Andrea ; Gardi, Mario ; Bassi, Pier Francesco. / Progression risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia. In: Archivio Italiano di Urologia e Andrologia. 2009 ; Vol. 81, No. 1. pp. 1-8.
@article{3b33eb9bf2d94f2b9ffdc9263c3e91d0,
title = "Progression risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.",
abstract = "Benign prostatic hyperplasia (BPH) is a chronic common disease in many men and is often associated with bothersome lower urinary tract symptoms (LUTS). In many men the disease presents with a progressive course that can result in complications such as acute urinary retention (AUR) and BPH-related surgery. Several factors have been associated with progression such as age and prostate volume (PV). Serum prostate-specific antigen (PSA) level, closely correlated with PV, is another useful parameter for determining the risk of BPH progression. Medical therapy is the first and the most frequently used treatment for BPH; surgical treatments rapresent a second-line option when medical therapy is non effective or when complications are associated. Alpha-blockers achieve rapid symptom relief but do not reduce the overall risk of AUR or BPH-related surgery, presumably because they have no effect on PV. 5alpha-reductase inhibitors (5ARIs) display their effectiveness at long distance decreasing PV; this results in improved symptoms, urinary flow and quality of life, and a reduced risk of AUR and BPH-related surgery. Combination therapy provides greater and more durable benefits than either monotherapy and is a recommended option in treatment guidelines. The Combination of dutasteride and Tamsulosin (CombAT), at a pre-planned 2-year analysis, has shown sustained symptom improvement with combination therapy, significantly greater than with either monotherapy. CombAT is also the first study to show benefit in improving BPH symptoms for combination therapy over the alpha-blocker, tamsulosin, from 9 months of treatment. PubMed database has been used to identify publications on the epidemiology of BPH, risk factors for BPH progression and drug treatment options for the management of BPH.",
keywords = "Benign prostatic hyperplasia, Diagnosis, Risk factors, Therapy.",
author = "Francesco Pinto and Marco Racioppi and Emilio Sacco and Angelo Totaro and Antonio Brescia and Andrea Volpe and Mario Gardi and Bassi, {Pier Francesco}",
year = "2009",
month = "3",
language = "English",
volume = "81",
pages = "1--8",
journal = "Archivio Italiano di Urologia Nefrologia Andrologia",
issn = "1120-8538",
publisher = "Edizioni Scripta Manent s.n.c.",
number = "1",

}

TY - JOUR

T1 - Progression risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.

AU - Pinto, Francesco

AU - Racioppi, Marco

AU - Sacco, Emilio

AU - Totaro, Angelo

AU - Brescia, Antonio

AU - Volpe, Andrea

AU - Gardi, Mario

AU - Bassi, Pier Francesco

PY - 2009/3

Y1 - 2009/3

N2 - Benign prostatic hyperplasia (BPH) is a chronic common disease in many men and is often associated with bothersome lower urinary tract symptoms (LUTS). In many men the disease presents with a progressive course that can result in complications such as acute urinary retention (AUR) and BPH-related surgery. Several factors have been associated with progression such as age and prostate volume (PV). Serum prostate-specific antigen (PSA) level, closely correlated with PV, is another useful parameter for determining the risk of BPH progression. Medical therapy is the first and the most frequently used treatment for BPH; surgical treatments rapresent a second-line option when medical therapy is non effective or when complications are associated. Alpha-blockers achieve rapid symptom relief but do not reduce the overall risk of AUR or BPH-related surgery, presumably because they have no effect on PV. 5alpha-reductase inhibitors (5ARIs) display their effectiveness at long distance decreasing PV; this results in improved symptoms, urinary flow and quality of life, and a reduced risk of AUR and BPH-related surgery. Combination therapy provides greater and more durable benefits than either monotherapy and is a recommended option in treatment guidelines. The Combination of dutasteride and Tamsulosin (CombAT), at a pre-planned 2-year analysis, has shown sustained symptom improvement with combination therapy, significantly greater than with either monotherapy. CombAT is also the first study to show benefit in improving BPH symptoms for combination therapy over the alpha-blocker, tamsulosin, from 9 months of treatment. PubMed database has been used to identify publications on the epidemiology of BPH, risk factors for BPH progression and drug treatment options for the management of BPH.

AB - Benign prostatic hyperplasia (BPH) is a chronic common disease in many men and is often associated with bothersome lower urinary tract symptoms (LUTS). In many men the disease presents with a progressive course that can result in complications such as acute urinary retention (AUR) and BPH-related surgery. Several factors have been associated with progression such as age and prostate volume (PV). Serum prostate-specific antigen (PSA) level, closely correlated with PV, is another useful parameter for determining the risk of BPH progression. Medical therapy is the first and the most frequently used treatment for BPH; surgical treatments rapresent a second-line option when medical therapy is non effective or when complications are associated. Alpha-blockers achieve rapid symptom relief but do not reduce the overall risk of AUR or BPH-related surgery, presumably because they have no effect on PV. 5alpha-reductase inhibitors (5ARIs) display their effectiveness at long distance decreasing PV; this results in improved symptoms, urinary flow and quality of life, and a reduced risk of AUR and BPH-related surgery. Combination therapy provides greater and more durable benefits than either monotherapy and is a recommended option in treatment guidelines. The Combination of dutasteride and Tamsulosin (CombAT), at a pre-planned 2-year analysis, has shown sustained symptom improvement with combination therapy, significantly greater than with either monotherapy. CombAT is also the first study to show benefit in improving BPH symptoms for combination therapy over the alpha-blocker, tamsulosin, from 9 months of treatment. PubMed database has been used to identify publications on the epidemiology of BPH, risk factors for BPH progression and drug treatment options for the management of BPH.

KW - Benign prostatic hyperplasia

KW - Diagnosis

KW - Risk factors

KW - Therapy.

UR - http://www.scopus.com/inward/record.url?scp=66249139881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66249139881&partnerID=8YFLogxK

M3 - Article

VL - 81

SP - 1

EP - 8

JO - Archivio Italiano di Urologia Nefrologia Andrologia

JF - Archivio Italiano di Urologia Nefrologia Andrologia

SN - 1120-8538

IS - 1

ER -